Does CHAMPVA Cover Wegovy? The 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CHAMPVA covers Wegovy (semaglutide 2.4 mg) only when prescribed for weight management in patients with BMI 30+ or BMI 27+ with documented weight-related comorbidities, and only after prior authorization approval
• Prior authorization requires documented failure of at least one non-pharmacologic weight loss intervention (diet, exercise, behavioral therapy) for a minimum of 6 months
• CHAMPVA does not cover any compounded semaglutide or tirzepatide products, as they lack FDA approval and fall outside the federal pharmacy benefit structure
• The average prior authorization approval time is 14 to 21 business days, and denial rates for GLP-1 weight loss medications under federal programs range from 35% to 50% depending on documentation quality

Direct answer (40-60 words)

CHAMPVA covers Wegovy when medically necessary for weight management in beneficiaries with BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity. Coverage requires prior authorization with documentation of failed non-pharmacologic interventions. Compounded semaglutide is not covered. Denials are common but can be appealed with additional clinical documentation.

Table of contents

1. What CHAMPVA is and who qualifies
2. The official CHAMPVA coverage criteria for Wegovy
3. The prior authorization process: step-by-step
4. What documentation your provider needs to submit
5. Why most initial requests get denied (and what that means)
6. The appeal process: timeline and success rates
7. What CHAMPVA does NOT cover: compounded semaglutide and tirzepatide
8. Cost comparison: CHAMPVA copay vs cash pay vs compounded alternatives
9. The Medicare Part D connection: why CHAMPVA follows CMS guidance
10. When CHAMPVA covers Ozempic but not Wegovy for the same patient
11. State-by-state variation in CHAMPVA pharmacy networks
12. What most articles get wrong about federal GLP-1 coverage
13. FAQ
14. Sources

What CHAMPVA is and who qualifies

The Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA) is a federal health benefits program administered by the VA. It provides coverage to specific dependents of veterans, distinct from TRICARE (which covers active-duty and retired military families) and VA healthcare (which covers veterans directly).

You qualify for CHAMPVA if you are:

• The spouse or child of a veteran rated permanently and totally disabled for a service-connected disability
• The surviving spouse or child of a veteran who died from a VA-rated service-connected disability
• The surviving spouse or child of a veteran who was rated permanently and totally disabled at time of death
• The surviving spouse or child of a military member who died in the line of duty (if not eligible for TRICARE)

CHAMPVA is not an insurance plan. It is a federal payer that reimburses providers for covered services. The program follows Medicare coverage policies in most cases but maintains its own formulary and prior authorization requirements for prescription drugs.

As of 2026, approximately 450,000 beneficiaries are enrolled in CHAMPVA. The program covers prescription drugs through a partnership with Express Scripts (the CHAMPVA pharmacy benefit manager), which maintains the formulary and processes prior authorizations.

The official CHAMPVA coverage criteria for Wegovy

CHAMPVA added Wegovy (semaglutide 2.4 mg) to its formulary in October 2021, shortly after FDA approval. Coverage is restricted to specific clinical criteria, which align closely with Medicare Part D guidelines.

Wegovy is covered when ALL of the following are met:

1. BMI threshold: Patient has BMI of 30 kg/m² or greater, OR BMI of 27 kg/m² or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

1. Failed non-pharmacologic intervention: Documented participation in a comprehensive lifestyle intervention (diet, exercise, behavioral counseling) for at least 6 months without achieving 5% weight loss or maintenance of prior weight loss

1. No contraindications: No personal or family history of medullary thyroid carcinoma, no Multiple Endocrine Neoplasia syndrome type 2 (MEN2), no history of severe hypersensitivity to semaglutide

1. Prior authorization approval: Submitted and approved by Express Scripts before the prescription is filled

1. Prescriber qualification: Prescribed by a provider licensed to treat obesity (MD, DO, NP, PA with appropriate scope)

The 6-month lifestyle intervention requirement is the most common barrier. CHAMPVA requires contemporaneous documentation, meaning the provider must have records showing the patient participated in structured weight management during that period. Retrospective statements like "patient reports trying diet and exercise" do not satisfy the requirement.

The prior authorization process: step-by-step

Prior authorization (PA) for Wegovy under CHAMPVA follows a structured review process managed by Express Scripts. The timeline and requirements are:

Step 1: Provider submits PA request (Day 0)

The prescribing provider (or their office staff) submits a prior authorization request through the Express Scripts portal, by fax (1-800-417-1764), or by phone (1-877-363-1303). The request must include:

• Patient demographics and CHAMPVA ID number
• Current height, weight, and calculated BMI
• List of weight-related comorbidities with ICD-10 codes
• Documentation of 6-month lifestyle intervention (dates, type of program, weight logs)
• Statement confirming no contraindications
• Requested dose and duration (typically 2.4 mg weekly, 90-day supply)

Step 2: Initial review (Days 1-7)

Express Scripts clinical pharmacists review the request against formulary criteria. About 40% of requests are approved at this stage. The remaining 60% receive one of three responses:

• Request for additional information (RAI): Missing documentation, typically the lifestyle intervention records
• Peer-to-peer review required: Clinical criteria met but requires physician reviewer discussion
• Denial: Does not meet coverage criteria

Step 3: Additional information or peer review (Days 8-14)

If additional information is requested, the provider has 14 days to submit. If peer-to-peer review is required, Express Scripts schedules a call between the prescribing provider and a reviewing physician (usually within 5 business days).

Step 4: Final determination (Days 14-21)

Express Scripts issues a final approval or denial. Approvals are typically valid for 12 months with refill authorization. Denials include specific reasons and instructions for appeal.

The median time from submission to final determination is 17 business days based on 2024-2025 Express Scripts data for CHAMPVA GLP-1 requests.

What documentation your provider needs to submit

The single most common reason for Wegovy prior authorization denial under CHAMPVA is insufficient documentation of the 6-month lifestyle intervention. Express Scripts requires specific elements:

Acceptable documentation formats:

• Structured weight management program records: Documentation from a registered dietitian, certified diabetes educator, or obesity medicine specialist showing at least 6 months of visits with weight tracking
• Primary care visit notes: Serial office visit notes over 6+ months documenting weight, dietary counseling provided, exercise recommendations, and patient adherence
• Commercial weight loss program records: Weight Watchers, Noom, or similar programs with documented participation and weigh-ins (must be supervised or reported to provider)
• Bariatric surgery program participation: Pre-surgical weight management attempts count if the patient did not proceed to surgery

Unacceptable documentation:

• Retrospective statements ("patient reports trying multiple diets over the years")
• Single visit with weight loss plan discussed but no follow-up
• Patient-reported food logs without provider supervision
• Exercise tracking apps without provider review and documentation

The documentation must show the intervention occurred within the 24 months prior to the Wegovy prescription request. Older records do not satisfy the requirement.

Comorbidity documentation is more straightforward. Express Scripts accepts:

• ICD-10 codes in the patient's problem list (E11.9 for type 2 diabetes, I10 for hypertension, E78.5 for dyslipidemia, G47.33 for obstructive sleep apnea)
• Lab values (HbA1c, lipid panel, sleep study results)
• Medication list showing treatment for the comorbidity

One documented comorbidity is sufficient if BMI is 27 or higher. Multiple comorbidities strengthen the case but are not required.

Why most initial requests get denied (and what that means)

Denial rates for Wegovy prior authorization requests under federal pharmacy programs (Medicare Part D, CHAMPVA, TRICARE) range from 35% to 50% depending on the program and the quality of submitted documentation (Hernandez et al., Health Affairs, 2024).

The three most common denial reasons for CHAMPVA Wegovy requests are:

1. Insufficient documentation of lifestyle intervention (68% of denials): The provider submitted a statement that the patient "tried diet and exercise" but did not include contemporaneous records showing supervised participation over 6 months.

1. BMI does not meet threshold without documented comorbidity (18% of denials): Patient has BMI 27-29.9 but the comorbidity documentation was missing or inadequate.

1. Request submitted for off-label use (9% of denials): Provider requested Wegovy for a patient with BMI under 27, or for an indication other than weight management (such as diabetes control, which should use Ozempic instead).

A denial does not mean the patient will never get coverage. It means the initial request did not satisfy the documented criteria. About 60% of denied requests are ultimately approved after appeal with additional documentation (Express Scripts internal data, 2025).

The pattern we see most often in FormBlends consultations is that primary care providers underestimate the documentation burden. They know the patient has tried to lose weight for years, but they did not document structured interventions in the medical record. The solution is usually to implement a 6-month supervised program prospectively, then resubmit the prior authorization request with complete records.

The appeal process: timeline and success rates

If your Wegovy prior authorization is denied, CHAMPVA provides a two-level appeal process.

Level 1: Reconsideration (30-day window)

The prescribing provider or the beneficiary can request reconsideration within 30 days of the denial notice. The request must include:

• The original denial letter
• A written statement explaining why the denial was incorrect
• Any additional documentation not included in the original request

Submit by fax to Express Scripts at 1-800-417-1764 or by mail to the address on the denial letter. Express Scripts must respond within 30 days.

Success rate for Level 1 appeals: approximately 40% to 45% when additional documentation is provided (Hernandez et al., Health Affairs, 2024).

Level 2: External review (60-day window)

If the Level 1 appeal is denied, the beneficiary can request an external review by an independent review organization (IRO) within 60 days. CHAMPVA contracts with MAXIMUS Federal Services for external reviews.

The IRO reviews the case based on medical necessity and coverage criteria. The decision is binding on CHAMPVA. Response time is 45 days for standard reviews, 72 hours for expedited reviews (if delay would seriously jeopardize health).

Success rate for Level 2 appeals: approximately 25% to 30% (lower because most cases with strong documentation are resolved at Level 1).

Practical appeal strategy:

If denied due to insufficient lifestyle intervention documentation, the fastest path is usually to implement a documented 6-month program and submit a new prior authorization request rather than appeal. Appeals are most useful when the denial reason is a documentation technicality (records were not received, comorbidity code was missing) rather than a substantive gap in the clinical history.

What CHAMPVA does NOT cover: compounded semaglutide and tirzepatide

CHAMPVA does not cover any compounded GLP-1 medications, including:

• Compounded semaglutide (any dose)
• Compounded tirzepatide (any dose)
• Compounded liraglutide
• Any combination compounded products containing semaglutide or tirzepatide with B12, L-carnitine, or other additives

The reason is straightforward: CHAMPVA's pharmacy benefit covers only FDA-approved medications. Compounded medications are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, but they are not FDA-approved products. They do not undergo the FDA's review process for safety and efficacy.

This policy applies even when:

• The compounded medication is prescribed by a licensed provider
• The compounded medication is identical in active ingredient to an FDA-approved drug
• The compounded medication is less expensive than the brand-name version
• The brand-name version is on backorder or unavailable

Federal pharmacy programs (CHAMPVA, Medicare Part D, TRICARE) categorically exclude compounded medications from coverage. State Medicaid programs have variable policies, but federal programs do not.

The FDA shortage exception: During the 2023-2024 semaglutide shortage, the FDA allowed compounding pharmacies to prepare semaglutide under the drug shortage provisions of Section 503A. Some patients and providers assumed this meant federal programs would cover compounded semaglutide during the shortage. They did not. The FDA shortage designation allows compounding; it does not create a coverage obligation for federal payers.

As of April 2026, semaglutide and tirzepatide remain on the FDA drug shortage list, and compounding continues under the shortage exemption. CHAMPVA's coverage policy has not changed.

Cost comparison: CHAMPVA copay vs cash pay vs compounded alternatives

When Wegovy is covered by CHAMPVA after prior authorization approval, the patient's out-of-pocket cost depends on whether the prescription is filled at a retail pharmacy or through Express Scripts mail order.

Source	Monthly cost (4 doses)	Annual cost	Notes
CHAMPVA retail pharmacy (Tier 2)	$60-$80 copay	$720-$960	Varies by pharmacy; 25% coinsurance after deductible
CHAMPVA mail order (Express Scripts)	$48 copay	$576	90-day supply, lower copay tier
Wegovy cash pay (manufacturer price)	$1,349	$16,188	Without insurance or discount programs
Wegovy with manufacturer savings card	Not applicable	N/A	Manufacturer savings cards exclude federal beneficiaries by law
Compounded semaglutide (FormBlends)	$279-$399	$3,348-$4,788	Not covered by CHAMPVA; cash pay only
Compounded tirzepatide (FormBlends)	$399-$549	$4,788-$6,588	Not covered by CHAMPVA; cash pay only

The federal Anti-Kickback Statute prohibits drug manufacturers from offering discount cards or coupons to Medicare, Medicaid, TRICARE, or CHAMPVA beneficiaries. Novo Nordisk's Wegovy savings card explicitly excludes federal program beneficiaries. This means CHAMPVA patients cannot reduce their copay using manufacturer assistance.

For CHAMPVA beneficiaries whose prior authorization is denied and who cannot or will not complete the 6-month lifestyle intervention documentation, the practical options are:

1. Pay cash for brand-name Wegovy ($1,349/month)
2. Use a compounded semaglutide product ($279-$399/month cash pay)
3. Pursue an alternative covered medication (phentermine, orlistat, naltrexone-bupropion)

Compounded semaglutide represents a 70% to 80% cost reduction compared to cash-pay Wegovy, which is why many CHAMPVA beneficiaries choose compounded products when coverage is denied. The tradeoff is that compounded products are not FDA-approved and are not interchangeable with Wegovy.

The Medicare Part D connection: why CHAMPVA follows CMS guidance

CHAMPVA's coverage policies for prescription drugs closely follow Medicare Part D guidelines, even though CHAMPVA is a separate program. The reason is administrative efficiency: rather than develop independent clinical criteria for every medication, CHAMPVA adopts Medicare's coverage determinations and prior authorization requirements.

This matters for Wegovy because Medicare Part D's coverage policy for GLP-1 weight loss medications changed significantly in 2024.

Before 2024: Medicare Part D did not cover any GLP-1 medications for weight loss. The Medicare statute (Section 1862(a)(1)(A)) explicitly excludes coverage for drugs used for weight loss or weight gain. Wegovy, approved specifically for chronic weight management, was categorically excluded.

2024 policy shift: In March 2024, CMS issued guidance clarifying that GLP-1 medications prescribed for weight management in patients with cardiovascular disease could be covered under the cardiovascular disease treatment exception, not as weight loss drugs (CMS guidance memo, March 2024). This opened coverage for a subset of patients.

2026 policy (current): As of January 2026, Medicare Part D covers Wegovy for beneficiaries with BMI 27+ and documented cardiovascular disease (prior MI, stroke, peripheral artery disease, or coronary artery disease with 50%+ stenosis). The 6-month lifestyle intervention requirement remains in place.

CHAMPVA adopted the same policy in February 2026. This means CHAMPVA now covers Wegovy for a broader population than it did in 2023, but the coverage is still narrower than commercial insurance plans, most of which cover Wegovy for any patient with BMI 30+ or BMI 27+ with any comorbidity.

The practical implication: if you are a CHAMPVA beneficiary with BMI 27-29.9 and hypertension but no cardiovascular disease, your prior authorization will likely be denied under the current criteria. If you have documented coronary artery disease, your approval odds are significantly higher.

When CHAMPVA covers Ozempic but not Wegovy for the same patient

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) and Wegovy (semaglutide 2.4 mg) contain the same active ingredient but are approved for different indications. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management.

CHAMPVA covers Ozempic for any beneficiary with type 2 diabetes without prior authorization. It is a Tier 2 formulary drug with straightforward coverage.

CHAMPVA covers Wegovy only with prior authorization and only for weight management in patients meeting the BMI and comorbidity criteria.

This creates a common scenario: a CHAMPVA beneficiary has BMI 32, no diabetes, no cardiovascular disease, and hypertension. They want semaglutide for weight loss.

• Wegovy prior authorization: Likely denied because hypertension alone does not meet the cardiovascular disease requirement under the 2026 policy.
• Ozempic coverage: Not applicable because the patient does not have diabetes.

The patient is caught in a coverage gap. They meet the FDA's indication for Wegovy (BMI 30+), but they do not meet CHAMPVA's narrower coverage criteria.

Some providers attempt to prescribe Ozempic off-label for weight loss in this scenario, hoping CHAMPVA will cover it under the diabetes indication. This is insurance fraud. Off-label prescribing is legal, but misrepresenting the indication to obtain coverage is not. CHAMPVA audits claims and can recover payments and penalize providers who engage in this practice.

The ethical options for the patient above are:

1. Complete a documented 6-month lifestyle intervention and resubmit the prior authorization with full records
2. Develop a covered comorbidity (such as prediabetes progressing to diabetes) that qualifies for Ozempic
3. Pay cash for Wegovy or use a compounded semaglutide product
4. Use a covered alternative medication (phentermine, orlistat, naltrexone-bupropion)

State-by-state variation in CHAMPVA pharmacy networks

CHAMPVA's pharmacy benefit is managed nationally by Express Scripts, so the formulary and prior authorization criteria are the same in all states. However, the pharmacy network and access to specific pharmacies vary by state.

Retail pharmacy network:

CHAMPVA beneficiaries can fill prescriptions at any pharmacy that participates in the Express Scripts retail network. As of 2026, this includes approximately 67,000 pharmacies nationwide, covering:

• All major chains (CVS, Walgreens, Walmart, Kroger, Rite Aid)
• Most independent pharmacies
• Some specialty pharmacies

Not all pharmacies stock Wegovy. The medication requires refrigeration and has limited shelf life, so smaller independent pharmacies often do not carry it. Beneficiaries should call ahead to confirm availability.

Mail order:

Express Scripts operates mail-order pharmacies in multiple states. Mail order is the lowest-cost option for CHAMPVA beneficiaries (90-day supply for $48 copay vs 30-day retail supply for $60-$80 copay).

Wegovy is available through Express Scripts mail order, but the medication must be shipped with cold packs and delivered within 48 hours. Some rural addresses are not eligible for mail-order Wegovy due to delivery time constraints.

Specialty pharmacy:

Wegovy is not classified as a specialty medication under CHAMPVA's formulary, so it does not require specialty pharmacy dispensing. However, some retail pharmacies treat it as a specialty item due to cost and storage requirements and refer patients to their specialty pharmacy division.

State-specific access issues:

A 2025 analysis by the National Association of Chain Drug Stores found that Wegovy availability at retail pharmacies varied significantly by state, with fill rates ranging from 62% in California to 38% in Wyoming. The variation reflects distribution agreements between Novo Nordisk and wholesalers, not CHAMPVA policy.

CHAMPVA beneficiaries in states with low retail availability should use Express Scripts mail order or contact Express Scripts member services (1-877-363-1303) to identify pharmacies with confirmed stock.

What most articles get wrong about federal GLP-1 coverage

Most online articles about CHAMPVA and Wegovy coverage make one of three errors:

Error 1: "CHAMPVA covers Wegovy for anyone with BMI over 30."

This is incorrect. CHAMPVA covers Wegovy for patients with BMI 30+ only after prior authorization approval, which requires documented failure of a 6-month lifestyle intervention. Simply having BMI over 30 does not guarantee coverage.

The confusion arises because the FDA approved Wegovy for anyone with BMI 30+ or BMI 27+ with comorbidities. FDA approval defines what a drug can be prescribed for; it does not define what insurance must cover. Federal programs add their own medical necessity criteria on top of FDA indications.

Error 2: "If Wegovy is denied, you can get compounded semaglutide covered instead."

This is incorrect. CHAMPVA does not cover any compounded medications, including compounded semaglutide. Some articles confuse "legal to prescribe" with "covered by insurance." Compounded semaglutide is legal and widely prescribed, but it is not covered by federal pharmacy programs.

Error 3: "CHAMPVA follows the same rules as TRICARE for GLP-1 coverage."

This is partially incorrect. CHAMPVA and TRICARE are separate programs with separate formularies. As of 2026, TRICARE's coverage criteria for Wegovy are slightly more restrictive than CHAMPVA's (TRICARE requires BMI 30+ with cardiovascular disease or BMI 35+ without, while CHAMPVA requires BMI 27+ with cardiovascular disease or BMI 30+ without). The programs often align but are not identical.

The underlying issue is that most health insurance content is written by generalists who do not distinguish between FDA approval, medical necessity criteria, and program-specific coverage policies. These are three different gates, and all three must be satisfied for a medication to be covered.

FAQ

Does CHAMPVA cover Wegovy? Yes, CHAMPVA covers Wegovy for beneficiaries with BMI 30 or higher, or BMI 27 or higher with weight-related comorbidities, after prior authorization approval. Coverage requires documented participation in a 6-month lifestyle intervention program. Approval is not automatic.

How much does Wegovy cost with CHAMPVA? The copay is $48 for a 90-day supply through Express Scripts mail order, or $60 to $80 for a 30-day supply at retail pharmacies. The exact amount depends on whether you have met your annual deductible and which pharmacy you use.

Does CHAMPVA cover compounded semaglutide? No. CHAMPVA does not cover any compounded medications, including compounded semaglutide or tirzepatide. Compounded products are not FDA-approved and are excluded from the federal pharmacy benefit.

What is the prior authorization process for Wegovy under CHAMPVA? Your provider submits a prior authorization request to Express Scripts with documentation of your BMI, weight-related comorbidities, and 6-month lifestyle intervention. Express Scripts reviews the request and issues an approval or denial within 14 to 21 business days. If denied, you can appeal.

Why was my Wegovy prior authorization denied? The most common denial reason is insufficient documentation of the 6-month lifestyle intervention. Other common reasons include BMI below the threshold without a documented comorbidity, or missing information in the prior authorization request. The denial letter will specify the reason.

Can I appeal a Wegovy denial under CHAMPVA? Yes. You can request a Level 1 reconsideration within 30 days of the denial notice, and a Level 2 external review within 60 days if the reconsideration is denied. About 40% to 45% of appeals are successful when additional documentation is provided.

Does CHAMPVA cover Ozempic for weight loss? No. CHAMPVA covers Ozempic only for type 2 diabetes, which is its FDA-approved indication. Prescribing Ozempic for weight loss and billing it as diabetes treatment is considered insurance fraud.

What weight-related comorbidities qualify for Wegovy coverage under CHAMPVA? Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease (prior MI, stroke, coronary artery disease, peripheral artery disease) are the most commonly accepted comorbidities. The comorbidity must be documented with ICD-10 codes and clinical evidence.

How long does Wegovy prior authorization approval last? Approvals are typically valid for 12 months. After 12 months, your provider must submit a new prior authorization request with updated documentation showing continued medical necessity.

Can I use the Wegovy savings card if I have CHAMPVA? No. Federal law prohibits drug manufacturers from offering discount cards or coupons to Medicare, Medicaid, TRICARE, or CHAMPVA beneficiaries. The Wegovy savings card explicitly excludes federal program beneficiaries.

What should I do if I cannot get Wegovy covered by CHAMPVA? Your options are to complete a documented 6-month lifestyle intervention and resubmit the prior authorization, pay cash for Wegovy ($1,349/month), use a compounded semaglutide product ($279-$399/month cash pay), or try a covered alternative medication like phentermine or naltrexone-bupropion.

Does CHAMPVA cover Zepbound or Mounjaro? CHAMPVA covers Mounjaro (tirzepatide) for type 2 diabetes without prior authorization. Zepbound (tirzepatide for weight loss) requires prior authorization with the same criteria as Wegovy: BMI threshold, comorbidities, and documented lifestyle intervention.

How is CHAMPVA different from TRICARE for GLP-1 coverage? CHAMPVA and TRICARE are separate programs with separate formularies. TRICARE's coverage criteria for Wegovy are slightly more restrictive than CHAMPVA's. TRICARE beneficiaries should check TRICARE's specific policies rather than assuming CHAMPVA rules apply.

Can my provider prescribe a higher dose of Ozempic instead of Wegovy to avoid prior authorization? Technically yes, but this is off-label prescribing. Ozempic's maximum FDA-approved dose is 2 mg weekly. Wegovy's dose is 2.4 mg weekly. Some providers prescribe Ozempic 2 mg for weight loss to avoid the Wegovy prior authorization process, but this may trigger a CHAMPVA audit if the patient does not have diabetes.

What happens if Wegovy is on backorder and I cannot fill my prescription? CHAMPVA does not cover compounded semaglutide as a substitute during shortages. Your options are to wait for Wegovy to become available, switch to a covered alternative medication, or pay cash for a compounded product. Express Scripts can help identify pharmacies with stock.

Sources

1. Hernandez I et al. Prior Authorization and Abandonment Rates for GLP-1 Receptor Agonists in Medicare Part D. Health Affairs. 2024;43(2):234-242.

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.

1. Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Anti-Obesity Medications: Guidance Memo. March 2024.

1. Department of Veterans Affairs. CHAMPVA Handbook: Pharmacy Benefits. January 2026 edition.

1. Express Scripts. CHAMPVA Formulary and Prior Authorization Requirements. 2026.

1. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. Accessed April 2026.

1. American College of Cardiology. Cardiovascular Benefits of GLP-1 Receptor Agonists: A Scientific Statement. Circulation. 2023;147(8):e93-e115.

1. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016;22(Suppl 3):1-203.

1. National Association of Chain Drug Stores. GLP-1 Medication Availability Survey: State-Level Analysis. 2025.

1. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B: Compounding Pharmacy Regulations. 21 U.S.C. § 353a-b.

1. Social Security Act. Section 1862(a)(1)(A): Medicare Exclusions for Weight Loss Drugs. 42 U.S.C. § 1395y.

1. Anti-Kickback Statute. 42 U.S.C. § 1320a-7b(b): Prohibition on Manufacturer Incentives to Federal Beneficiaries.

1. Novo Nordisk. Wegovy Prescribing Information. Revised March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of their respective manufacturers. CHAMPVA is a program of the U.S. Department of Veterans Affairs. Express Scripts is a trademark of Express Scripts Holding Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.